Abstract
Current antiangiogenic therapies have led to the observation that such agents can lead to improved tumor vessel structure and function termed “vascular normalization” which reduces tumor burden. However, vessel normalization is a transient process, and patients often develop resistance/poor response to anti-vascular strategies that remains an important clinical challenge. Therefore, increasing effort has been made to better understand the cellular and molecular mechanisms of vascular normalization and its contribution to immunomodulation. Herein, we summarize the recent effort to better understand the cellular and molecular mechanisms of vascular normalization with a focus on preclinical genetic models. These studies remain important directions for a mechanistic understanding of the complexities of the maintenance of BBB integrity and the impact of its breakdown on tumor dissemination and pharmaco-distribution of therapeutics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622
Liebner S, Czupalla CJ, Wolburg H (2011) Current concepts of blood–brain barrier development. Int J Dev Biol 55:467–476
Ek CJ, Dziegielewska KM, Stolp H et al (2006) Functional effectiveness of the blood–brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). J Comp Neurol 496:13–26
Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7:41–53
Thompson EM, Frenkel EP, Neuwelt EA (2011) The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76:87–93
Lee J, Borboa AK, Chun HB et al (2010) Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood–brain barrier in glioma. Cancer Res 70:10131–10140
de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233–242
McGee MC, Hamner JB, Williams RF et al (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76:1537–1545
von Baumgarten L, Brucker D, Tirniceru A et al (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17:6192–6205
Goel S, Duda DG, Xu L et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121
Folkins C, Man S, Xu P et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560–3564
Kesari S, Schiff D, Doherty L et al (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9:354–363
Mazzone M, Dettori D, Leite de Oliveira R et al (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839–851
Yang H, Lee S, Kim K et al (2013) Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. J Clin Invest 123:418–431
Armulik A, Genove G, Mae M et al (2010) Pericytes regulate the blood–brain barrier. Nature 468:557–561
Bell RD, Winkler EA, Sagare AP et al (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68:409–427
Hamzah J, Jugold M, Kiessling F et al (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453:410–414
Sawada J, Urakami T, Li F et al (2012) Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 22:235–249
Falcon BL, Hashizume H, Koumoutsakos P et al (2009) Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175:2159–2170
Nasarre P, Thomas M, Kruse K et al (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69:1324–1333
Van de Veire S, Stalmans I, Heindryckx F et al (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141:178–190
Chen XL, Nam JO, Jean C et al (2012) VEGF-induced vascular permeability is mediated by FAK. Dev Cell 22:146–157
Wong CS, Sceneay J, House CM et al (2012) Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. Cancer Res 72:1694–1704
Stockmann C, Doedens A, Weidemann A et al (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456:814–818
Rolny C, Mazzone M, Tugues S et al (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19:31–44
Diop-Frimpong B, Chauhan VP, Krane S et al (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 108:2909–2914
Chen P, Bonaldo P (2013) Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol 301:1–35
Dilnawaz F, Singh A, Mewar S et al (2012) The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 33:2936–2951
Kong SD, Lee J, Ramachandran S et al (2012) Magnetic targeting of nanoparticles across the intact blood–brain barrier. J Control Release 164:49–57
Wohlfart S, Gelperina S, Kreuter J (2011) Transport of drugs across the blood–brain barrier by nanoparticles. J Control Release 161:264–273
Liu J, Liao S, Huang Y et al (2011) PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 17:3638–3648
Leite de Oliveira R, Deschoemaeker S, Henze AT et al (2012) Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 22:263–277
Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563
Sennino B, McDonald DM (2012) Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12:699–709
Fokas E, Im JH, Hill S et al (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72:239–248
Cerniglia GJ, Pore N, Tsai JH et al (2009) Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4:e6539
Jain RK, Duda DG, Clark JW et al (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24–40
Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lee, J., Baird, A., Eliceiri, B.P. (2014). Vascular Normalization in Cerebral Angiogenesis: Friend or Foe?. In: Milner, R. (eds) Cerebral Angiogenesis. Methods in Molecular Biology, vol 1135. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0320-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0320-7_3
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0319-1
Online ISBN: 978-1-4939-0320-7
eBook Packages: Springer Protocols